



PT TAISHO PHARMACEUTICAL INDONESIA TBK.

Head Office: Millennium Centennial Center 8th fl, Jl. Jend. Sudirman Kav. 25, Jakarta 12920, INDONESIA

Phone: +62 21 3970 6720, Fax: +62 21 3972 6735

Technical Operations: Jl. Raya Jakarta-Bogor Km. 38, Cilangkap, Tapos (Depok) 16458, INDONESIA
Phone: +62 21 875 2583 / 875 2584

PENGUMUMAN

RAPAT UMUM PEMEGANG SAHAM TAHUNAN dan **RAPAT UMUM PEMEGANG SAHAM LUAR BIASA** **PT TAISHO PHARMACEUTICAL INDONESIA TBK**

-Dengan ini diumumkan kepada para pemegang saham PT Taisho Pharmaceutical Indonesia Tbk, berkedudukan di Jakarta Selatan dan beralamat di Millennium Centennial Center, Lt. 8, Jl. Jend. Sudirman Kav. 25, Jakarta 12920 (“Perseroan”) bahwa Perseroan akan menyelenggarakan Rapat Umum Pemegang Saham Tahunan (“RUPST”) dan Rapat Umum Pemegang Saham Luar Biasa (“RUPSLB”) di Jakarta pada hari Rabu, tanggal 30 April 2025.

-Pemanggilan RUPST dan RUPSLB tersebut akan dilakukan pada tanggal 8 April 2025.

-Para pemegang saham yang berhak hadir dalam RUPST dan RUPSLB tersebut adalah pemegang saham Perseroan yang namanya tercatat dengan sah dalam Daftar Pemegang Saham Perseroan pada tanggal 27 Maret 2025 pukul 16:00 Waktu Indonesia Barat atau kuasa mereka yang sah.

-Setiap pemegang saham Perseroan berhak mengusulkan acara rapat untuk dimasukkan dalam agenda RUPST atau RUPSLB jika memenuhi persyaratan dalam ayat 21.5 Pasal 21 Anggaran Dasar Perseroan, yakni (i) pemegang saham yang mengusulkan secara sendiri atau bersama-sama mewakili sedikitnya 1/20 (satu per dua puluh) bagian dari jumlah semua saham yang telah dikeluarkan Perseroan dengan hak suara yang sah, (ii) dilakukan dengan itikad baik, (iii) mempertimbangkan kepentingan Perseroan, (iv) menyertakan alasan dan bahan usulan mata acara, dan (v) tidak bertentangan dengan peraturan perundang-undangan yang berlaku.

-Usulan mata acara, jika ada, dimohon untuk disampaikan kepada Direksi Perseroan sedikitnya 7 (tujuh) hari sebelum tanggal pemanggilan RUPST/RUPSLB.

-RUPSLB akan membahas rencana perubahan kegiatan usaha Perseroan dan perubahan Pasal 3 Anggaran Dasar Perseroan dan perubahan status Perseroan dari Perusahaan Terbuka menjadi Perusahaan Tertutup (Go Private). Keterbukaan Informasi kepada Pemegang Saham Perseroan mengenai rencana Perubahan Kegiatan Usaha Perseroan dan Go Private tersebut diumumkan bersamaan dengan pengumuman untuk RUPS/RUPSLB ini.

Jakarta, 21 Maret 2025

Direksi Perseroan



PT TAISHO PHARMACEUTICAL INDONESIA TBK.

Head Office: Millennium Centennial Center 8th fl, Jl. Jend. Sudirman Kav. 25, Jakarta 12920, INDONESIA

Phone: +62 21 3970 6720, Fax: +62 21 3972 6735

Technical Operations: Jl. Raya Jakarta-Bogor Km. 38, Cilangkap, Tapos (Depok) 16458, INDONESIA
Phone: +62 21 875 2583 / 875 2584

ANNOUNCEMENT OF
ANNUAL GENERAL MEETING OF SHAREHOLDERS and
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
OF PT TAISHO PHARMACEUTICAL INDONESIA TBK

-It is hereby announced to the shareholders of PT Taisho Pharmaceutical Indonesia Tbk, domiciled in South Jakarta and having its address at Millennium Centennial Center, 8th Floor, Jl. Jend. Sudirman Kav. 25, Jakarta 12920 (the “**Company**”) that the Company will convene an Annual General Meeting of Shareholders (“**AGM**”) and an Extraordinary General Meeting of Shareholders (“**EGM**”) in Jakarta on Wednesday, 30 April 2025.

-The notices for such AGM and EGM will be made on 8 April 2025.

-The shareholders who are entitled to attend the AGM and EGM shall be those shareholders of the Company whose names are validly registered in the Register of Shareholders of the Company on 27 March 2025 at 04:00 pm West Indonesia Time or their lawful attorney.

-Each shareholder of the Company shall be entitled to propose agenda item to be included in the agenda items of the AGM or EGM if the requirements under paragraph 21.5 of Article 21 of the Articles of Association of the Company, namely: (i) the proposing shareholder, individually or collectively represent at least 1/20 (one twentieth) of the total number of shares with legal voting rights issued by the Company, (ii) being submitted in good faith, (iii) considering the interest of the Company, (iv) include reasons and materials of the proposed agenda items, and (v) do not conflict with the prevailing rules and legislations.

-The proposed agenda items, if any, are kindly requested to be submitted to the Board of Directors of the Company at least 7 (seven) days prior to the date of notices for the AGM/EGM.

-The EGM will discuss the proposed change in the Company's business activities and amendments to Article 3 of the Company's Articles of Association and the change of the Company's status from a Public Company to become Private Company (Go Private). Disclosure of Information to the Company's Shareholders regarding the proposed Change in the Company's Business Activities and Go Private are announced simultaneously with the announcement for this AGM/EGM.

Jakarta, 21 March 2025
Board of Directors of the Company